» Articles » PMID: 9430646

Nucleo-cytoplasmic Shuttling of the Hdm2 Oncoprotein Regulates the Levels of the P53 Protein Via a Pathway Used by the Human Immunodeficiency Virus Rev Protein

Overview
Journal EMBO J
Date 1998 Feb 28
PMID 9430646
Citations 198
Authors
Affiliations
Soon will be listed here.
Abstract

The hdm2 gene is overexpressed in a variety of human tumors. Its gene product localizes predominantly to the nucleus, where it acts as an inhibitor of the p53 tumor suppressor gene product. It is shown here that the hdm2 oncoprotein constantly shuttles between the nucleus and the cytoplasm. Shuttling of hdm2 does not depend on its interaction with p53. Nuclear export of hdm2 is mediated by a signal sequence similar to the nuclear export signal of the rev protein from human immunodeficiency virus and other lentiviruses. Mutation of this signal sequence abolishes detectable nucleo-cytoplasmic shuttling. When fused to a carrier protein, the hdm2 signal sequence can mediate nuclear export after intranuclear microinjection into HeLa cells. The export of hdm2 can be blocked by a competitive inhibitor of rev export, arguing that the export pathways for hdm2 and rev are either overlapping or identical. Inhibition of its export modifies the ability of hdm2 to block p53-mediated transcriptional activation, and hdm2's export function is required to accelerate the degradation of p53. Thus the rev nuclear export pathway may be used to regulate an oncogene product's activity and modulate cellular growth.

Citing Articles

The Ubiquitination of Arrestin3 within the Nucleus Triggers the Nuclear Export of Mdm2, Which, in Turn, Mediates the Ubiquitination of GRK2 in the Cytosol.

Kundu D, Min X, Zhang X, Tian X, Wang S, Kim K Int J Mol Sci. 2024; 25(17).

PMID: 39273591 PMC: 11395016. DOI: 10.3390/ijms25179644.


Gene alterations in the nuclear transport receptor superfamily: A study of head and neck cancer.

Nguyen P, Shimojukkoku Y, Kajiya Y, Oku Y, Tomishima A, Shima K PLoS One. 2024; 19(5):e0300446.

PMID: 38820302 PMC: 11142601. DOI: 10.1371/journal.pone.0300446.


Angiotensin-Converting Enzyme 2 Posttranslational Modifications and Implications for Hypertension and SARS-CoV-2: 2023 Lewis K. Dahl Memorial Lecture.

Elgazzaz M, Filipeanu C, Lazartigues E Hypertension. 2024; 81(7):1438-1449.

PMID: 38567498 PMC: 11168885. DOI: 10.1161/HYPERTENSIONAHA.124.22067.


Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression.

Zhou Y, Nakajima R, Shirasawa M, Fikriyanti M, Zhao L, Iwanaga R Biology (Basel). 2023; 12(12).

PMID: 38132337 PMC: 10740672. DOI: 10.3390/biology12121511.


MDM2 amplification is rare in gastric cancer.

Abdullazade S, Behrens H, Kruger S, Haag J, Rocken C Virchows Arch. 2023; 483(6):795-807.

PMID: 37821635 PMC: 10700221. DOI: 10.1007/s00428-023-03674-8.


References
1.
Oliner J, Kinzler K, Meltzer P, GEORGE D, Vogelstein B . Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992; 358(6381):80-3. DOI: 10.1038/358080a0. View

2.
Momand J, Zambetti G, Olson D, George D, Levine A . The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69(7):1237-45. DOI: 10.1016/0092-8674(92)90644-r. View

3.
Moll U, Riou G, Levine A . Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A. 1992; 89(15):7262-6. PMC: 49686. DOI: 10.1073/pnas.89.15.7262. View

4.
Ladanyi M, Cha C, Lewis R, Jhanwar S, Huvos A, Healey J . MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 1993; 53(1):16-8. View

5.
Finlay C . The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol. 1993; 13(1):301-6. PMC: 358909. DOI: 10.1128/mcb.13.1.301-306.1993. View